Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic oncology research group (TORG) 1017

Yoshiro Nakahara, Yukio Hosomi, Masahiko Shibuya, Hisashi Mitsufuji, Masato Katagiri, Katsuhiko Naoki, Kenzo Soejima, Naoyuki Nogami, Seisuke Nagase, Masanori Nishikawa, Koichi Minato, Yuichi Takiguchi, Nobuhiko Seki, Kouzo Yamada, Takashi Seto, Hiroaki Okamoto

Research output: Contribution to journalArticle

Abstract

Skeletal-related events (SREs) may occur at the time of first diagnosis in 20-30% of lung cancer patients with bone metastases. Several clinical trials have shown that zoledronic acid (ZA) is effective for decreasing SREs. The main objective of the present study was to discuss clinical data of ZA and compare the frequency of SREs with previous reports. All patients with non-small-cell lung cancer (NSCLC) with metastatic bone disease who were administered ZA at least twice between January 2008 and December 2009 were eligible for inclusion in the study. In total, 198 consecutive patients were identified. The median duration of ZA administration was 106 days [95% confidence interval (CI), 92-133 days], and the median number of ZA administrations was 4 (range, 2-41). The median time to first SRE in patients who experienced SRE following ZA treatment was 202 days (95% CI, 156-264 days). Among the 78 patients who had already experienced SRE prior to ZA treatment, 35 (45%) experienced SRE subsequently after starting ZA treatment. On the other hand, among the 120 patients without a history of SRE before starting ZA treatment, 42 (35%) experienced SRE after the start of ZA administration (P=0.16). No osteonecrosis of the jaw (ONJ) was reported in any of the patients. The present study revealed that ZA had a certain level of efficacy regardless of the presence or absence of prior SREs. However, the duration of ZA therapy was short in this study; further accumulation of data on the long-term prognosis and incidence rates of ONJ and other late complications of ZA therapy seems to be particularly important.

Original languageEnglish
Pages (from-to)349-353
Number of pages5
JournalMolecular and Clinical Oncology
Volume11
Issue number4
DOIs
Publication statusPublished - 2019 Oct

Fingerprint

zoledronic acid
Non-Small Cell Lung Carcinoma
Multicenter Studies
Thorax
Neoplasm Metastasis
Bone and Bones
Research
Osteonecrosis
Jaw
Therapeutics

Keywords

  • bone metastases
  • non-small-cell lung cancer
  • zoledronic acid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis : Thoracic oncology research group (TORG) 1017. / Nakahara, Yoshiro; Hosomi, Yukio; Shibuya, Masahiko; Mitsufuji, Hisashi; Katagiri, Masato; Naoki, Katsuhiko; Soejima, Kenzo; Nogami, Naoyuki; Nagase, Seisuke; Nishikawa, Masanori; Minato, Koichi; Takiguchi, Yuichi; Seki, Nobuhiko; Yamada, Kouzo; Seto, Takashi; Okamoto, Hiroaki.

In: Molecular and Clinical Oncology, Vol. 11, No. 4, 10.2019, p. 349-353.

Research output: Contribution to journalArticle

Nakahara, Y, Hosomi, Y, Shibuya, M, Mitsufuji, H, Katagiri, M, Naoki, K, Soejima, K, Nogami, N, Nagase, S, Nishikawa, M, Minato, K, Takiguchi, Y, Seki, N, Yamada, K, Seto, T & Okamoto, H 2019, 'Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic oncology research group (TORG) 1017', Molecular and Clinical Oncology, vol. 11, no. 4, pp. 349-353. https://doi.org/10.3892/mco.2019.1903
Nakahara, Yoshiro ; Hosomi, Yukio ; Shibuya, Masahiko ; Mitsufuji, Hisashi ; Katagiri, Masato ; Naoki, Katsuhiko ; Soejima, Kenzo ; Nogami, Naoyuki ; Nagase, Seisuke ; Nishikawa, Masanori ; Minato, Koichi ; Takiguchi, Yuichi ; Seki, Nobuhiko ; Yamada, Kouzo ; Seto, Takashi ; Okamoto, Hiroaki. / Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis : Thoracic oncology research group (TORG) 1017. In: Molecular and Clinical Oncology. 2019 ; Vol. 11, No. 4. pp. 349-353.
@article{436abd2024804860ba5c870369dbeae0,
title = "Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic oncology research group (TORG) 1017",
abstract = "Skeletal-related events (SREs) may occur at the time of first diagnosis in 20-30{\%} of lung cancer patients with bone metastases. Several clinical trials have shown that zoledronic acid (ZA) is effective for decreasing SREs. The main objective of the present study was to discuss clinical data of ZA and compare the frequency of SREs with previous reports. All patients with non-small-cell lung cancer (NSCLC) with metastatic bone disease who were administered ZA at least twice between January 2008 and December 2009 were eligible for inclusion in the study. In total, 198 consecutive patients were identified. The median duration of ZA administration was 106 days [95{\%} confidence interval (CI), 92-133 days], and the median number of ZA administrations was 4 (range, 2-41). The median time to first SRE in patients who experienced SRE following ZA treatment was 202 days (95{\%} CI, 156-264 days). Among the 78 patients who had already experienced SRE prior to ZA treatment, 35 (45{\%}) experienced SRE subsequently after starting ZA treatment. On the other hand, among the 120 patients without a history of SRE before starting ZA treatment, 42 (35{\%}) experienced SRE after the start of ZA administration (P=0.16). No osteonecrosis of the jaw (ONJ) was reported in any of the patients. The present study revealed that ZA had a certain level of efficacy regardless of the presence or absence of prior SREs. However, the duration of ZA therapy was short in this study; further accumulation of data on the long-term prognosis and incidence rates of ONJ and other late complications of ZA therapy seems to be particularly important.",
keywords = "bone metastases, non-small-cell lung cancer, zoledronic acid",
author = "Yoshiro Nakahara and Yukio Hosomi and Masahiko Shibuya and Hisashi Mitsufuji and Masato Katagiri and Katsuhiko Naoki and Kenzo Soejima and Naoyuki Nogami and Seisuke Nagase and Masanori Nishikawa and Koichi Minato and Yuichi Takiguchi and Nobuhiko Seki and Kouzo Yamada and Takashi Seto and Hiroaki Okamoto",
year = "2019",
month = "10",
doi = "10.3892/mco.2019.1903",
language = "English",
volume = "11",
pages = "349--353",
journal = "Molecular and Clinical Oncology",
issn = "2049-9450",
number = "4",

}

TY - JOUR

T1 - Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis

T2 - Thoracic oncology research group (TORG) 1017

AU - Nakahara, Yoshiro

AU - Hosomi, Yukio

AU - Shibuya, Masahiko

AU - Mitsufuji, Hisashi

AU - Katagiri, Masato

AU - Naoki, Katsuhiko

AU - Soejima, Kenzo

AU - Nogami, Naoyuki

AU - Nagase, Seisuke

AU - Nishikawa, Masanori

AU - Minato, Koichi

AU - Takiguchi, Yuichi

AU - Seki, Nobuhiko

AU - Yamada, Kouzo

AU - Seto, Takashi

AU - Okamoto, Hiroaki

PY - 2019/10

Y1 - 2019/10

N2 - Skeletal-related events (SREs) may occur at the time of first diagnosis in 20-30% of lung cancer patients with bone metastases. Several clinical trials have shown that zoledronic acid (ZA) is effective for decreasing SREs. The main objective of the present study was to discuss clinical data of ZA and compare the frequency of SREs with previous reports. All patients with non-small-cell lung cancer (NSCLC) with metastatic bone disease who were administered ZA at least twice between January 2008 and December 2009 were eligible for inclusion in the study. In total, 198 consecutive patients were identified. The median duration of ZA administration was 106 days [95% confidence interval (CI), 92-133 days], and the median number of ZA administrations was 4 (range, 2-41). The median time to first SRE in patients who experienced SRE following ZA treatment was 202 days (95% CI, 156-264 days). Among the 78 patients who had already experienced SRE prior to ZA treatment, 35 (45%) experienced SRE subsequently after starting ZA treatment. On the other hand, among the 120 patients without a history of SRE before starting ZA treatment, 42 (35%) experienced SRE after the start of ZA administration (P=0.16). No osteonecrosis of the jaw (ONJ) was reported in any of the patients. The present study revealed that ZA had a certain level of efficacy regardless of the presence or absence of prior SREs. However, the duration of ZA therapy was short in this study; further accumulation of data on the long-term prognosis and incidence rates of ONJ and other late complications of ZA therapy seems to be particularly important.

AB - Skeletal-related events (SREs) may occur at the time of first diagnosis in 20-30% of lung cancer patients with bone metastases. Several clinical trials have shown that zoledronic acid (ZA) is effective for decreasing SREs. The main objective of the present study was to discuss clinical data of ZA and compare the frequency of SREs with previous reports. All patients with non-small-cell lung cancer (NSCLC) with metastatic bone disease who were administered ZA at least twice between January 2008 and December 2009 were eligible for inclusion in the study. In total, 198 consecutive patients were identified. The median duration of ZA administration was 106 days [95% confidence interval (CI), 92-133 days], and the median number of ZA administrations was 4 (range, 2-41). The median time to first SRE in patients who experienced SRE following ZA treatment was 202 days (95% CI, 156-264 days). Among the 78 patients who had already experienced SRE prior to ZA treatment, 35 (45%) experienced SRE subsequently after starting ZA treatment. On the other hand, among the 120 patients without a history of SRE before starting ZA treatment, 42 (35%) experienced SRE after the start of ZA administration (P=0.16). No osteonecrosis of the jaw (ONJ) was reported in any of the patients. The present study revealed that ZA had a certain level of efficacy regardless of the presence or absence of prior SREs. However, the duration of ZA therapy was short in this study; further accumulation of data on the long-term prognosis and incidence rates of ONJ and other late complications of ZA therapy seems to be particularly important.

KW - bone metastases

KW - non-small-cell lung cancer

KW - zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=85073393413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073393413&partnerID=8YFLogxK

U2 - 10.3892/mco.2019.1903

DO - 10.3892/mco.2019.1903

M3 - Article

AN - SCOPUS:85073393413

VL - 11

SP - 349

EP - 353

JO - Molecular and Clinical Oncology

JF - Molecular and Clinical Oncology

SN - 2049-9450

IS - 4

ER -